Skip to main
DNTH
DNTH logo

DNTH Stock Forecast & Price Target

DNTH Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Dianthus Therapeutics Inc. is experiencing a positive outlook due to its significant advancements in developing novel monoclonal antibodies aimed at treating severe autoimmune and inflammatory diseases, particularly with their DNTH103 asset. The company has seen upward adjustments in target pricing, with recent estimates rising from $44 to $46, attributed to improved net cash positions and a reduced share count, enhancing the financial foundation for future growth. Furthermore, clinical trial progress and favorable comparisons with existing therapies are validating the company's innovative approach and strengthening investor confidence in its long-term potential.

Bears say

Dianthus Therapeutics faces significant challenges in advancing its pipeline due to potential difficulties in raising adequate funds, which could hinder its development plans. The decision to remove an assumed offering in FY28 and lower the FY25 share count indicates a tightening financial situation that may impact the company's capital structure and operational capabilities. These factors contribute to a negative outlook on the company's ability to execute its strategic initiatives effectively.

DNTH has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Magenta Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Magenta Therapeutics Inc (DNTH) Forecast

Analysts have given DNTH a Strong Buy based on their latest research and market trends.

According to 8 analysts, DNTH has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $68, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $68, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Magenta Therapeutics Inc (DNTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.